ADVERTISEMENT

Dr. Reddy’s - Growth Story Intact: Nirmal Bang

Dr. Reddy’s - Growth Story Intact: Nirmal Bang

<div class="paragraphs"><p>Dr. Reddy's Laboratories R&amp;D facility (Source: Company website).</p></div>
Dr. Reddy's Laboratories R&D facility (Source: Company website).

BQ Prime’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BQ Prime’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.

Nirmal Bang Report

We attended the Investor Day Conference of Dr. Reddy’s Laboratories Ltd. to understand the company’s future business outlook. The overarching themes at the conference were related to achieving sustainability through renewed focus on environmental, social and governance considerations and striving to achieve double-digit revenue growth while simultaneously maintaining Ebitda margin and return on capital employed of ~25% in the medium term.

The management has emphasised on increasing patient reach with a goal of serving 1.5 billion plus patients globally by 2030 (three times company’s current patient base).

Dr. Reddy's will follow a two-pronged approach in its journey to achieve profitable growth:

  1. Growth in core businesses, including generics, active pharma ingredient, biosimilars, over-the-counter and branded generics (Horizon 1, short medium term growth drivers).

  2. Building capabilities in areas that can be meaningful in the short to long term. These areas include immuno-oncology new chemical entities, biologics, cell gene therapy, nutraceuticals, contract development and manufacturing organisation, among others. (Horizon 2, short-long term growth drivers).

Click on the attachment to read the full report:

Nirmal Bang Dr Reddys Laboratories-Investor Meet Update-22 June 2022.pdf

DISCLAIMER

This report is authored by an external party. BQ Prime does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BQ Prime.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.